Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study
Br J Dermatol
.
2023 Mar 30;188(4):454-455.
doi: 10.1093/bjd/ljad005.
Authors
Simone Cazzaniga
1
2
,
Luigi Naldi
2
3
,
Luca Borradori
1
Affiliations
1
Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland.
2
Centro Studi GISED, Bergamo, Italy.
3
Division of Dermatology, San Bortolo Hospital, Vicenza, Italy.
PMID:
36722006
DOI:
10.1093/bjd/ljad005
No abstract available
Publication types
Editorial
Comment
MeSH terms
Azathioprine
Cohort Studies
Humans
Mycophenolic Acid
Pemphigus* / drug therapy
Pemphigus* / epidemiology
Rituximab / adverse effects
Treatment Outcome
Substances
Rituximab
Azathioprine
Mycophenolic Acid